title: Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.
abstract: The reported selective serotonin Re-uptake Inhibitor Litoxetine was used as the starting point in the design of a range of potential SSRIs with high ease of synthetic accessibility. Preparation and subsequent optimization yielded a range of potent and highly selective SSRIs.
authors.affiliation: Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom.
authors.forename: Mark
authors.initials: M
authors.lastname: Andrews
authors.forename: Alan
authors.initials: A
authors.lastname: Brown
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Chiva
authors.forename: David
authors.initials: D
authors.lastname: Fradet
authors.forename: David
authors.initials: D
authors.lastname: Gordon
authors.forename: Mark
authors.initials: M
authors.lastname: Lansdell
authors.forename: Malcolm
authors.initials: M
authors.lastname: MacKenny
mesh_terms: D002460:Cell Line; D015195:Drug Design; D006801:Humans; D010880:Piperidines / Q000138:chemical synthesis / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D010880:Piperidines; D017367:Selective Serotonin Reuptake Inhibitors; C057048:litoxetine